Navigation Links
Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration

ing to its pituitary receptor LHRH triggers the release of luteinizing hormone, a key factor for the regulation of reproductive function. Continuous administration of exogenous LHRH or its agonists such as triptorelin leads to a rapid desensitization of its pituitary receptor resulting in a paradoxical effect that translates into the suppression of gonadal steroids such as testosterone and estradiol. This chemically induced and reversible castration is of therapeutic benefit in the treatment of hormone sensitive tumours such as breast and prostate. Triptorelin is the active ingredient of Decapeptyl(R) and Diphereline(R) available as 1- and 3-month sustained release formulations registered for the treatment of advanced metastatic hormone-dependent prostate cancer.

About Ipsen

Ipsen is an innovation driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) which are growth drivers, and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2006, R&D expenditure was EUR 178.3 million, i.e. 20.7% of consolidated sales, which amounted to EUR 861.7 million while total revenues amounted to EUR 945.3 million (in IFRS). 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Systeme a Reglement Differe" ("SRD") and the Group is p
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/4/2015)... 2015  Luminex Corporation (NASDAQ: LMNX ) today ... Global Healthcare Conference to be held September 16 - ... New York City . The ... on Friday, September 18, 2015.  The presentation will be webcast ... at http://www.luminexcorp.com . Simply log on to the web ...
(Date:9/4/2015)... , Sept. 4, 2015  Cumberland Pharmaceuticals (CPIX), today ... present live at VirtualInvestorConferences.com on September 10, 2015. ... ET LINK: http://tinyurl.com/sep10pre ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:9/4/2015)... Research and Markets ... the "Pharmacovigilance (London, UK - December 7-9, ... Understanding PhV today - the principles and practice ... safety. This course aims to provide ... entrants as well as experienced operators in drug ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2
... CHANGZHOU, China, July 28, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings ... leading domestic developer, manufacturer and marketer of orthopedic implants in ... quarter 2011 financial results on August 16, 2011, before the ... at 8:00 a.m. ET on August 16, 2011 to discuss ...
... (NYSE Amex: CXM ) today provided an update ... business assets in connection with a proposed asset purchase under ... June 27, 2011, the completion of such an asset purchase ... the bankruptcy court.  In an effort to expedite the proposed ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4
(Date:9/4/2015)... , ... September 04, 2015 , ... ... three separate “Partner of the Year” awards at this year’s Microsoft Worldwide Partner ... Microsoft’s 2015 “Partner of the Year” Award Winner for Data Platform services, the ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors and distractions ... and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons ... the island’s only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel ...
(Date:9/4/2015)... Pass, OR (PRWEB) , ... September 04, 2015 ... ... that markets a line of personal humidifying medical devices, announced its only mission ... climate, explains Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... , ... Steven Winter Associates, Inc., (SWA) is pleased to ... the Residential Award of Merit by the Connecticut Green Building Council (CTGBC) for ... competitive field of submissions, the net-zero energy residence will be honored at the ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2
... is available in French . Montreal, November ... the marketplace, thanks to a new partnership between Gestion ... a privately owned technology company based in Montreal. ... and its affiliated institutions, and CSI have announced the ...
... Nov. 25, 2009 Physicians at UT Southwestern Medical Center ... breathing in patients with upper spinal-cord injuries or other diseases ... University Hospital St. Paul is only one of only ... country currently equipped to implant the device, called the NeuRx ...
... success for patients with liver lesions, researchers find , ... cetuximab to neoadjuvant chemotherapy can shrink tumors and boost ... with inoperable metastatic liver lesions, new research suggests. ... the body in more than half of patients with ...
... Two experts offer waistline-friendly ways to enjoy festive feasting , ... five-week holiday smorgasbord from Thanksgiving to New Year,s, but are ... off come Jan. 1, help is at hand. , It,s ... make it to 2010 weighing the same as you ...
... ... natural treatments to complement conventional methods. , ... Burnaby, BC (Vocus) November 25, 2009 -- While surgery, chemotherapy ... turn to alternative medicine to help them cope with the side effects of conventional ...
... ... a new market research report is available in its ... (2nd Edition) , http://www.reportlinker.com/p0165301/The-Market-for-Anti-ageing-Foods-(2nd-Edition ).html , ... a fast pace with growth outstripping that of conventional ...
Cached Medicine News:Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2Health News:Cetuximab Helps Treat Colorectal Cancer 2Health News:Holiday Eating Without the Guilt -- or the Pounds 2Health News:Holiday Eating Without the Guilt -- or the Pounds 3Health News:Holistic and Western Medicine Combined Can Fight Cancer 2Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 2Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 3Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 4Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 5Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 6Health News:Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition) 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: